Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

O'Byrne, Ken

doi:http://dx.doi.org/10.1016/j.cllc.2018.03.009

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

Files

1-s2.0-S1525730418300512-main.pdf (798.44 KB)

Date

2018

Authors

O'Byrne, Ken

Access

openAccess

Citation

Wu, Y.-L. and Sequist, L.V. and Tan, E.-H. and Geater, S.L. and Orlov, S. and Zhang, L. and Lee, K.H. and Tsai, C.-M. and Kato, T. and Barrios, C.H. and Schuler, M. and Hirsh, V. and Yamamoto, N. and O'Byrne, K. and Boyer, M. and Mok, T. and Peil, B. and M??rten, A. and Chih-Hsin Yang, J. and Paz-Ares, L. and Park, K., Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials, Clinical Lung Cancer, 19, 4, 2018, e465-e479